## Abstract

Juvenile amyotrophic lateral sclerosis (ALS) is a form of chronic motor neuron disease characterized by combined upper and lower motor neuron symptoms and signs with onset prior to age 25 years. We report the clinical and electrodiagnostic findings in 49 affected family members and neuropathological findings from two autopsies of a Maryland kindred with autosomal dominant juvenile ALS linked to the chromosome 9q34 region (ALS4). Patients ranged in age from 12 to 85 years (mean 45 years) and the mean age of onset was 17 years. Distal weakness and atrophy was associated with pyramidal signs (43/49) and normal sensation (44/49). Motor conduction studies (n = 8) showed reduced evoked amplitudes and normal conduction parameters. Sensory conduction studies (n = 8), quantitative sensory testing (n = 4) and intracutaneous sensory fibres in skin biopsies (n = 6) were normal in all patients tested. Electromyography showed distal more than proximal chronic partial denervation and reinnervation (n = 8). Post-mortem spinal cord tissue demonstrated atrophic spinal cords with marked loss of anterior horn cells and degeneration of corticospinal tracts, as well as loss of neurons in the dorsal root ganglia and degeneration of the posterior columns. Axonal spheroids were present in the grey matter of the spinal cord, the dorsal root entry zones and the peripheral nerves. Motor and sensory roots, as well as peripheral nerves, showed significant axonal loss. Swellings were prominent around motor neurons, probably representing changes in presynaptic terminals. These studies define autosomal dominant juvenile ALS linked to the chromosome 9q34 region (ALS4) and extend the clinical, pathological and genetic heterogeneity of familial ALS and juvenile ALS.

## Introduction

Motor neuron disease refers to a group of neurodegenerative disorders characterized by progressive weakness and atrophy of skeletal muscle due to the selective degeneration of motor neurons. Amyotrophic lateral sclerosis (ALS) is a form of motor neuron disease that is usually fatal, and it is characterized by clinical and pathological features of upper and lower motor neuron degeneration. Approximately 90% of ALS cases are sporadic and 10% are familial (Emery and Holloway, 1982). Up to 20% of families with familial ALS carry a mutation in the superoxide dismutase gene (SOD1) (Rosen et al., 1993). For the majority of families with familial ALS, the gene defect and pathogenesis are unknown.

Progressive upper and lower motor neuron signs are also found in a group of juvenile-onset motor neuron disorders with different clinical and genetic patterns. In general, the term juvenile ALS has been used for patients with onset of disease prior to age 25 years and prolonged survival (Ben Hamida et al., 1990). Most cases of juvenile ALS are autosomal recessive, although autosomal dominant inheritance patterns have been described (Ben Hamida et al., 1990). Recessive forms of juvenile ALS have been mapped to chromosome regions 2q33 (ALS2) (Hentati et al., 1994a; Siddique et al., 1996) and 15q12–21 (Hentati et al., 1994a, 1997).

Four years prior to the publication of Dyck and Lambert's classification scheme for Charcot–Marie–Tooth disease (Dyck and Lambert, 1968a, b), Myrianthopoulos and co-workers described three families with this disease (Myrianthopoulos et al., 1964). Family D was a large Maryland kindred with an autosomal disorder characterized by weakness, atrophy and pyramidal signs. Re-examination of two members of this family who had previous diagnoses of Charcot–Marie–Tooth disease showed distal weakness and amyotrophy, hyper-reflexia and normal sensation, findings not consistent with the current concept of this disease. In this report, we describe the findings of our re-examination of this large Maryland family, including the first two autopsies. Genetic studies have shown linkage to the 9q34 region (Chance et al., 1998). As a result of this investigation, we reclassify this family as having juvenile ALS. These studies broaden the spectrum of disease classified as juvenile ALS to include a non-fatal form with autosomal dominant inheritance (termed ALS4) and further define the clinical and pathological heterogeneity seen in heritable forms of motor neuron disease.

## Methods

### Patients

This study was approved by the ethics committee of Johns Hopkins University School of Medicine and Johns Hopkins Hospital, and informed consent was obtained from all participating family members or their legal surrogates prior to inclusion in the study.

All patients were examined by at least two of the authors, either at Johns Hopkins or at a family reunion in June 1994. In total, 150 family members have been examined to date. Criteria for inclusion as affected were: (i) corticospinal tract signs; (ii) distally predominant weakness and amyotrophy; and (iii) absence of confounding neurological illness. Previous medical records were reviewed and used to aid classification of individual patients. Motor strength was graded by the Medical Research Council (MRC) scale (Medical Research Council, 1986). Tendon reflexes were graded as 0–4: 0 = absent; 1 = hypoactive; 2 = normal; 3 = brisk; 4 = pathological with clonus.

### Electrodiagnostic studies

Electrodiagnostic studies were performed with standard techniques. Quantitative sensory testing was performed using the Case IV machine (WR Electronics, Stillwater, Minn., USA).

### Skin biopsy

Skin biopsies were performed on six individuals for evaluation of cutaneous nerve fibres (McCarthy et al., 1995), a technique particularly useful for visualizing the small sensory nerve fibres within the epidermis (Holland et al., 1998).

### Neuropathology

Portions of brain and spinal cord tissues from patients VII-10 and VIII-18 were collected, and each specimen was divided into three portions: one was fixed in 4% paraformaldehyde for paraffin sections, one was fixed in 5% glutaraldehyde and postfixed in osmium tetroxide for plastic embedding and one was frozen in dry ice–isobutane for cryostat sections. Sections stained with haematoxylin and eosin were prepared from each paraffin block of spinal cord and brain tissue. Selected sections were then processed with the following special stains: haematoxylin and eosin with Luxol fast blue counterstain; Hirano (modified Bielschowsky) silver stain; Masson trichrome stain; Congo red stain; modified Thioflavin S stain. Immunohistochemical stains were prepared using antibodies to identify the following antigens: glial fibrillary acidic protein (Dako, Carpinteria, Calif., USA), ubiquitin (Dako), and phosphorylated and non-phosphorylated epitopes of the 200 kDa neurofilament protein recognized by the antibodies SMI-31 and SMI-32, respectively (Sternberger Monoclonals, Inc., Baltimore, Md., USA). Plastic sections of spinal cord, ventral and dorsal roots, dorsal root ganglia and peripheral nerve were stained with toluidine blue. Thin sections were stained with lead citrate and uranyl acetate.

## Results

### Clinical findings

We examined 150 individuals from a large Maryland kindred. This family has traced its American roots back to the 1600s, when its ancestors arrived from England. Forty-nine patients had clinical signs (Table 1). There were 26 females and 23 males, and males and females both had a mean age of symptom onset of 17 years (Table 2). However, if clinically affected but asymptomatic patients are included in this analysis, the overall age of onset rises to 23 years (27 years for females and 15 years for males).

Six of our patients did not have upper motor neuron signs. Five of these patients (VII-10, VIII-8, VIII-18, VIII-20 and IX-43) had weakness and atrophy too severe at the time of initial examination for these signs to be elicited. The one remaining patient (IX-11) had a normal examination, but because his son (X-12) appeared affected we have tentatively classified him as an obligate carrier who is so far unaffected.

Increased vibratory thresholds at the great toes were present in five (10%) of our patients (VII-19, VIII-18, IX-20, IX-39 and X-12), although none had sensory symptoms. Only two patients (VIII-20 and X-19) had cranial nerve dysfunction; both of these patients had facial weakness. No patient had respiratory or bulbar weakness.

Interestingly, 22% (11/49) of the patients had unambiguous upper and lower motor neuron signs but were asymptomatic at the time of initial evaluation. The eight asymptomatic female patients (VIII-21, VIII-31, IX-10, IX-18, IX-24, IX-41, X-5 and X-22) ranged in age from 35 to 71 years. They account for 16% of all the patients and 31% of the female patients. Of the asymptomatic male patients, two are teenagers in whom it may be too early for them to notice symptoms, and the other is patient IX-11, mentioned above.

### Skin biopsies

Six individuals, ranging in age from 19 to 60 years, underwent skin biopsies to examine intracutaneous nerve fibres. All had normal densities and morphology of the intra-epidermal nerve fibres.

### Case reports

#### Patient IX-5

This patient was 60 years old when examined. His symptoms began in his early 30s with difficulty in walking. His disease progressed over the next 25 years to the point where he was unable to walk and had weakness in his hands. At the time of examination he denied dysarthria, dysphagia or dyspnoea. He had MRC grade 4 strength proximally in the arms and MRC grade 1 strength in the intrinsic hand muscles. Proximal lower limb strength was MRC grade 2 with flaccid paralysis distally. Deep tendon reflexes were grade 4 in the upper limbs, grade 1 at the knees with crossed adductors and absent at the ankles. His toes were unresponsive to plantar stimulation and sensation was normal. He had four sisters, two unaffected and two mildly affected, and three brothers, all asymptomatic. However, one of his siblings (IX-11) with a normal neurological examination had an affected son (X-12).

#### Patient X-12

This patient was a nephew of patient IX-5. He was 36 years old when examined. With the exception of a club foot at birth, he had normal development. Symptoms began at age 18 years with weak ankles and development of a limp. His disease progressed slowly, and he eventually noticed weakness in his upper limbs. There was knee flexion weakness (MRC grade 4), severe weakness in the ankle plantar flexors (MRC grade 1) and paralysis of the ankle dorsiflexors. In the upper limbs, proximal strength was normal but intrinsic hand muscles showed mild weakness (MRC grade 4). Tendon reflexes were grade 3 in the arms, grade 3 at the knees with crossed adductor reflexes, and absent at the ankles. Plantar responses were flexor.

#### Patient IX-26

This patient was 45 years old when examined. Her symptoms began when she was a teenager, with decreasing ability to run or jump. Her weakness progressed to the point where she was unable to walk up stairs at the time of examination. She noticed weakness in her hands and had great difficulty performing tasks requiring fine motor control. She had distal amyotrophy, normal strength proximally in the upper limbs, MRC grade 4 strength in the intrinsic hand and proximal lower limb muscles, grade 4 ankle dorsiflexor strength and grade 4 ankle plantar flexor strength. Tendon reflexes were grade 4 at the biceps, grade 3 at the triceps, grade 2 at the knees with crossed adductor reflexes, and absent at the ankles with extensor plantar responses. Sensation was normal.

#### Patient X-19

This patient, who was the son of patient IX-26, had onset of symptoms early in life, with weakness first noticed by his mother at age 1 year. His clinical course since then has been one of slow but steady progression. He was 19 years old when examined. There was facial weakness, normal strength proximally and MRC grade 4 strength in the distal limbs. Deep tendon reflexes were grade 3 in the arms, grade 2 at the knees and grade 1 at the ankles. He had bilateral extensor plantar responses. Sensation was normal.

### Neuropathology

Autopsies limited to the nervous system were performed on two patients. Patient VII-10 died of respiratory failure shortly after an ischaemic stroke in the left middle cerebral artery territory at age 88 years. Patient VIII-18 died of pneumonia at age 75 years.

#### Patient VII-10

##### Brain.

Brain weight prior to fixation was 1110 g. On gross examination, the most striking finding was a large area of acute ischaemic infarction involving the territories supplied by the left middle cerebral artery, particularly the left frontal and parietal lobes. However, ischaemic damage was also evident in the left cingulate gyrus, the caudate nucleus, the occipital pole and the CA1 region of the hippocampus. In the brainstem, the most striking pathological changes were in the dentate and nucleus gracilis, where ubiquitin-positive axonal swellings (spheroids) were numerous. Spheroids were also present in the intracranial parts of the third and fourth cranial nerves. The hypoglossal nucleus was normal.

#### Patient VIII-18

##### Brain.

Brain weight prior to fixation was 1180 g. Coronal sections demonstrated mild ventricular enlargement. Patchy gliosis was seen in the grey and white matter. Mild to moderate neuron loss was present in the hypoglossal nucleus and dorsal motor nucleus of the vagus. Large cytoplasmic inclusions were present in some neurons of the hypoglossal nucleus. These inclusions stained with both the Hirano silver stain and the ubiquitin immunostain.

## Discussion

The Maryland kindred described in this report has an autosomal dominant, early-onset, neurodegenerative disease characterized by progressive amyotrophy, weakness, pathological hyper-reflexia with abnormal spread of reflexes, and extensor plantar responses. Sensation was normal in 90% of the subjects, the rest having minimal, exclusively distal sensory signs. Anterior horn cell dysfunction was evident in patients who underwent electrodiagnostic testing but there was no evidence of peripheral neuropathy from electrophysiological studies, quantitative sensory testing or skin biopsy. Thus, affected individuals have typical clinical features of ALS, viz. progressive, unambiguous upper and lower motor neuron dysfunction in the absence of significant sensory abnormalities or ataxia. Given the age of onset of 17 years and the chronicity of the disease, this disorder should now be classified as juvenile ALS.

Analysis of two autopsy specimens demonstrated marked loss of spinal motor neurons in the anterior horns and less pronounced degeneration of the corticospinal tracts. Surprisingly, we also found myelin pallor in the posterior columns, marked axonal degeneration in peripheral nerve (sural, peroneal and phrenic nerves), dorsal and ventral roots and dorsal root ganglia. Together, these findings extend the clinical and pathological boundaries of juvenile ALS.

The patients described in this report, as well as the ALS2 patients described by Ben Hamida and co-workers with autosomal recessive juvenile ALS from Tunisia (Hentati et al., 1994a) and those previously reported by Refsum (Refsum and Skillicorn, 1954), all have early-onset diseases that are characterized by amyotrophy, weakness and pyramidal dysfunction but appear to be clinically and genetically distinct. Many ALS2 patients develop bulbar and respiratory weakness (Hentati et al., 1994b), whereas none of the ALS4 patients examined so far has significant respiratory or bulbar signs or symptoms. The relative lack of bulbar and respiratory muscle weakness in most of our patients also distinguishes them from sporadic ALS (Charcot and Joffroy, 1869) and familial ALS (Kurland and Mulder, 1955; Figlewicz and Rouleau, 1994). Interestingly, we and others have not yet been able to demonstrate accumulation of ubiquitinated inclusions in the cytoplasm of neurons of juvenile ALS patients (Matsumoto et al., 1993). However, ubiquitin-positive material is present in axonal spheroids (see Results).

Genetic mapping studies have confirmed the heterogeneity of the juvenile-onset diseases. We have previously reported linkage of autosomal dominant juvenile ALS (ALS4) to markers on chromosome 9q34 (Chance et al., 1998), while the autosomal recessive forms are linked to markers on chromosomes 2q33–35 (Hentati et al., 1994b; Siddique et al., 1996) and 15q12–21 (Hentati et al., 1997).

Although the clinical spectrum of familial ALS is much broader than that of sporadic ALS, we considered whether or not this family represented a form of neurodegenerative disease other than juvenile ALS. Selective motor system disease involving pyramidal tract dysfunction in the absence of bulbar weakness is also seen in hereditary spastic paraplegia (HSP) (Harding, 1981). The pure form of HSP is genetically heterogeneous with early onset, autosomal dominant HSP families showing linkage to chromosomes 14q (Hazan et al., 1993), 2p (Hazan et al., 1994; Hentati et al., 1994c) and 15q (Fink et al., 1995), while some families with autosomal recessive HSP have shown linkage to markers on chromosome 8q12–13 (Hentati et al., 1994b). Linkage to markers on Xq22 (PLP gene) and Xq28 (L1CAM gene) has also been shown (Keppen et al., 1987). However, since pure HSP patients do not have amyotrophy or other signs of lower motor neuron dysfunction, our family does not have pure HSP. In addition, our previous genetic studies have excluded the known HSP loci (Chance et al., 1998). Families with complicated' HSP have been reported with upper and lower motor neuron dysfunction (Garland and Astley, 1950; Cross and McKusick, 1967; Harding and Thomas, 1984), although many of these families have additional findings, such as optic atrophy, mental retardation and/or sensory signs (Webb et al., 1998). HSP with amyotrophy' patients appear to differ from our patients by the presence of marked spasticity, particularly in the lower limbs, and amyotrophy found predominantly in the upper limbs. The patients we have described have little or no spasticity and marked amyotrophy is present in both upper and lower limbs. In addition, the neuropathologies of these diseases differ significantly. HSP is characterized pathologically by axonal degeneration of the distal portions of the longest axons in the CNS: corticospinal tracts to the legs, fasciculus gracilis and spinocerebellar fibres. Diffuse axonal swellings are not a prominent feature.

Silver described two families with early-onset HSP characterized by amyotrophy and weakness of the hands and relatively mild pyramidal disease in the legs (Silver, 1966). A similar disorder was reported by van Gent and co-workers (van Gent et al., 1985). These patients had an early-onset (second decade) autosomal dominant disease characterized by pyramidal tract dysfunction associated with amyotrophy. Three of the 18 affected patients developed sensory symptoms late in their course and were thought to have either HSP with amyotrophy or hereditary motor and sensory neuropathy type V. Patients with the latter disease also have some features in common with ALS4 patients, including upper and lower motor neuron dysfunction (Harding, 1981, 1984). However, they have clear sensory signs and electrophysiological evidence of neuropathy rather than neuronopathy (Dyck, 1975). Another series of patients with an autosomal dominant, juvenile-onset disease characterized by upper and lower motor neuron dysfunction was reported in 1904 (Ormerod, 1904). The possibility that these patients, as well as those described by Silver and by van Gent, had a form of juvenile ALS similar to our family cannot be excluded by the information provided in either report, and was also considered by the authors (van Gent et al., 1985; Silver, 1966). It is possible that genetic studies in these families would confirm the heterogeneity.

Although the finding of posterior column pathology was surprising given the lack of clinical signs or symptoms, the prominent involvement of non-motor systems, particularly the posterior columns, has been well described in familial ALS (Engel et al., 1959; Hirano et al., 1967; Metcalf and Hirano 1971; Tanaka et al., 1984; Murayama et al., 1989; Takahashi et al., 1994; Shibata et al., 1996; Chudkowicz et al., 1998). Patients with this form of familial ALS typically present with progressive muscular atrophy and weakness associated with pyramidal dysfunction that may have a very slow clinical course. Many of these patients have objective sensory findings. Some families with familial ALS with posterior column involvement' have been shown to carry the A4V (Shibata et al., 1996; Chudkowicz et al., 1998) and A4T mutations (Takahashi et al., 1994) in SOD1. These patients may have associated clinical features of dysaesthesia, hypaesthesia and hypalgesia. Autopsy of a patient with the A4T mutation showed marked atrophy of the anterior horns, mild degeneration of the corticospinal tracts and prominent degeneration of the posterior columns and spinocerebellar tracts (Takahashi et al., 1994). It is not known why the posterior columns are involved in some but not all SOD1-linked familial ALS individuals. Similarly, expression of the G37R, G93A and A4V superoxide dismutase 1 mutations in transgenic mice results in mice with similar motor neuron disease phenotypes but significantly different pathological findings (Dal Canto and Gurney, 1995; Wong et al., 1995). These results highlight the fact that clinical expression of a specific, genetically defined disease is variable and depends on multiple genetic and environmental factors.

Why the pathological findings involving sensory pathways in our juvenile ALS patients are not associated with sensory symptoms or abnormalities on nerve conduction testing, quantitative sensory testing or skin biopsy remains unexplained. Only five patients had sensory signs, and these were solely of distal vibratory sensation loss. One possibility is that the pathological changes seen in sensory systems represent preclinical changes. Another possibility is that these changes are seen only late in the disease process or in end-stage disease. However, we have examined patients with severe disease and those late in life, and they have little or no sensory dysfunction.

In summary, we have described a large juvenile ALS family whose pathological findings include anterior horn cell and corticospinal tract degeneration, diffuse axonal swellings, degeneration in nerve roots and peripheral nerves, and prominent posterior column involvement. These findings extend the spectrum of familial ALS and juvenile ALS to include a slowly progressive, autosomal dominant, non-fatal but debilitating disease. Whether this family represents an intermediate form of motor neuron disease or a unique disease resulting from a primary abnormality of the axon must await further elucidation of the underlying defect in the gene responsible on chromosome 9q34.

Table 1

Clinical features of autosomal dominant juvenile ALS (ALS4)

Patient Age at exam (years) Onset age (years) Sex Amyotrophy Arm strength Leg strength Reflexes Plantar response Sensation
Ta
Patient numbers correspond to those in the paper by Chance et al. (Chance et al. 1998). Onset age: AS = asymptomatic. Strength was measured using the MRC scale. Arm strength: D = deltoid; B = biceps; T = triceps; W = wrist extensors; I = interossei. Leg strength: Q = quadriceps; H = hamstring; Ta = tibialis anterior; G = gastrocnemius. Reflexes are graded on a scale of 0–4: 0 = areflexia; 1 = reduced reflex; 2 = normal; 3 = brisk; 4 = clonus. Deep tendon reflexes: B = biceps; T = triceps; P = patella; A = ankle. Plantar responses: FP = flexor plantar; EP = extensor plantar; NR = no response. Sensation: nl = normal; dec = decreased.
VII-10 85 20 NR nl
VII-19 73 FP dec
VIII-8 66 28 NR nl
VIII-12 62 35 FP nl
VIII-15 62 40 FP nl
VIII-17 51 18 FP nl
VIII-18 71 10 NR dec
VIII-20 71 24 FP nl
VIII-21 71 AS FP nl
VIII-23 66 12 FP nl
VIII-24 43 12 FP nl
VIII-28 41 12 EP nl
VIII-31 34 AS FP nl
VIII-39 63 63 FP nl
VIII-36 67 20 EP nl
IX-1 45 15 FP nl
IX-3 44 13 FP nl
IX-5 60 35 FP nl
IX-10 64 AS EP nl
IX-11 62 AS FP nl
IX-13 58 12 FP nl
IX-16 53 FP nl
IX-18 60 AS EP nl
IX-20 41 31 FP dec
IX-21 39 33 FP nl
IX-23 34 10 EP nl
IX-24 28 AS EP nl
IX-26 47 20 FP nl
IX-29 44 10 FP nl
IX-31 31 15 FP nl
IX-36 15 14 FP nl
IX-37 12 AS FP nl
IX-39 44 NR dec
IX-41 35 AS FP nl
IX-43 65 FP nl
X-1 24 14 FP nl
X-5 35 AS FP nl
X-11 35 13 FP nl
X-12 36 18 FP dec
X-13 38 FP nl
X-14 33 FP nl
X-18 27 FP nl
X-19 19 EP nl
X-22 37 AS FP nl
X-23 32 15 EP nl
X-24 41 14 NR nl
XI-1 13 10 FP nl
XI-4 15 AS FP nl
XI-5 14 12 FP nl
Patient Age at exam (years) Onset age (years) Sex Amyotrophy Arm strength Leg strength Reflexes Plantar response Sensation
Ta
Patient numbers correspond to those in the paper by Chance et al. (Chance et al. 1998). Onset age: AS = asymptomatic. Strength was measured using the MRC scale. Arm strength: D = deltoid; B = biceps; T = triceps; W = wrist extensors; I = interossei. Leg strength: Q = quadriceps; H = hamstring; Ta = tibialis anterior; G = gastrocnemius. Reflexes are graded on a scale of 0–4: 0 = areflexia; 1 = reduced reflex; 2 = normal; 3 = brisk; 4 = clonus. Deep tendon reflexes: B = biceps; T = triceps; P = patella; A = ankle. Plantar responses: FP = flexor plantar; EP = extensor plantar; NR = no response. Sensation: nl = normal; dec = decreased.
VII-10 85 20 NR nl
VII-19 73 FP dec
VIII-8 66 28 NR nl
VIII-12 62 35 FP nl
VIII-15 62 40 FP nl
VIII-17 51 18 FP nl
VIII-18 71 10 NR dec
VIII-20 71 24 FP nl
VIII-21 71 AS FP nl
VIII-23 66 12 FP nl
VIII-24 43 12 FP nl
VIII-28 41 12 EP nl
VIII-31 34 AS FP nl
VIII-39 63 63 FP nl
VIII-36 67 20 EP nl
IX-1 45 15 FP nl
IX-3 44 13 FP nl
IX-5 60 35 FP nl
IX-10 64 AS EP nl
IX-11 62 AS FP nl
IX-13 58 12 FP nl
IX-16 53 FP nl
IX-18 60 AS EP nl
IX-20 41 31 FP dec
IX-21 39 33 FP nl
IX-23 34 10 EP nl
IX-24 28 AS EP nl
IX-26 47 20 FP nl
IX-29 44 10 FP nl
IX-31 31 15 FP nl
IX-36 15 14 FP nl
IX-37 12 AS FP nl
IX-39 44 NR dec
IX-41 35 AS FP nl
IX-43 65 FP nl
X-1 24 14 FP nl
X-5 35 AS FP nl
X-11 35 13 FP nl
X-12 36 18 FP dec
X-13 38 FP nl
X-14 33 FP nl
X-18 27 FP nl
X-19 19 EP nl
X-22 37 AS FP nl
X-23 32 15 EP nl
X-24 41 14 NR nl
XI-1 13 10 FP nl
XI-4 15 AS FP nl
XI-5 14 12 FP nl
Table 2

Summary of clinical data from affected autosomal dominant juvenile ALS individuals

Characteristic Female Male Total
*Age at symptom onset includes only symptomatic patients (see text).
Number of patients 26 23 49
Age at time of examination (mean, years) 51 38
Age at symptom onset (mean, years)* 17 17
Amyotrophy 22 (85%) 22 (96%) 44 (90%)
Upper limb weakness 21 (81%) 23 (91%) 44 (90%)
Lower limb weakness 23 (88%) 22 (96%) 45 (92%)
Pyramidal signs 23 (88%) 20 (87%) 43 (88%)
Sensory involvement  2 (8%)  3 (13%)  5 (10%)
Cranial nerve dysfunction  1 (4%)  1 (4%)  2 (4%)
Asymptomatic  8 (31%)  3 (13%) 11 (22%)
Characteristic Female Male Total
*Age at symptom onset includes only symptomatic patients (see text).
Number of patients 26 23 49
Age at time of examination (mean, years) 51 38
Age at symptom onset (mean, years)* 17 17
Amyotrophy 22 (85%) 22 (96%) 44 (90%)
Upper limb weakness 21 (81%) 23 (91%) 44 (90%)
Lower limb weakness 23 (88%) 22 (96%) 45 (92%)
Pyramidal signs 23 (88%) 20 (87%) 43 (88%)
Sensory involvement  2 (8%)  3 (13%)  5 (10%)
Cranial nerve dysfunction  1 (4%)  1 (4%)  2 (4%)
Asymptomatic  8 (31%)  3 (13%) 11 (22%)
Table 3

Nerve conduction studies of autosomal dominant juvenile ALS patients

Patient Nerve Distal latency Distal amplitude (μv) Conduction velocity (m/s) F-wave latency
s = sensory; m = motor; NT = not tested. Normal values: sensory amplitude >9 μV; sensory conduction velocity >39 m/s in legs and >49 m/s in arms; motor amplitude >2000 μV in the legs and >4000 μV in the arms; motor conduction velocity >39 m/s in the legs and >49 m/s in the arms; distal latency (motor), deep peroneal <5.6 ms, median <4.3 ms, ulnar <3.5 ms; F wave latency: deep peroneal <55 ms, median <32 ms, ulnar <33 ms.
VIII-40 Sural (s)  20 41
Deep peroneal (m) 5.8 2000 41 54.5
Median (s)  35 59
Median (m) 3.4 9500 59 31.9
IX-26 Sural (s)  15 44
Deep peroneal (m) 4.0 2400 46 48.0
Median (s)  39  57
Median (m) 2.9 5900 53 30.3
X-19 Sural (s)  19  58
Deep peroneal (m) 4.4 700 35 NT
Median (s)  34 67
Median (m) 3.6 6700 61 31.1
X-14 Sural (s)  30 53
Deep peroneal (m) 4.3 990 46 NT
Median (s)  41 61
Median (m) 3.1 5200 54 NT
IX-23 Sural (s)  23 42
Deep peroneal (m) 5.6 130 42 NT
Median (s)  39 64
Median (m) 4.5 200 36 NT
VIII-24 Sural (s)  11 44
Deep peroneal (m) 3.3 1100 49 NT
Ulnar (s)  13 56
Ulnar (m) 2.4 6000 58 31.3
X-23 Sural (s)  13 42
Deep peroneal (m) 5.1 2000 50 49.0
Median (s)  61 55
Median (m) 3.1 13 400 55 27.0
VIII-12 Sural (s)  20 40
Deep peroneal (m) 5.1 2000 40 54.9
Median (s)  20 56
Median (m) 3.6 4700 56 30.8
Patient Nerve Distal latency Distal amplitude (μv) Conduction velocity (m/s) F-wave latency
s = sensory; m = motor; NT = not tested. Normal values: sensory amplitude >9 μV; sensory conduction velocity >39 m/s in legs and >49 m/s in arms; motor amplitude >2000 μV in the legs and >4000 μV in the arms; motor conduction velocity >39 m/s in the legs and >49 m/s in the arms; distal latency (motor), deep peroneal <5.6 ms, median <4.3 ms, ulnar <3.5 ms; F wave latency: deep peroneal <55 ms, median <32 ms, ulnar <33 ms.
VIII-40 Sural (s)  20 41
Deep peroneal (m) 5.8 2000 41 54.5
Median (s)  35 59
Median (m) 3.4 9500 59 31.9
IX-26 Sural (s)  15 44
Deep peroneal (m) 4.0 2400 46 48.0
Median (s)  39  57
Median (m) 2.9 5900 53 30.3
X-19 Sural (s)  19  58
Deep peroneal (m) 4.4 700 35 NT
Median (s)  34 67
Median (m) 3.6 6700 61 31.1
X-14 Sural (s)  30 53
Deep peroneal (m) 4.3 990 46 NT
Median (s)  41 61
Median (m) 3.1 5200 54 NT
IX-23 Sural (s)  23 42
Deep peroneal (m) 5.6 130 42 NT
Median (s)  39 64
Median (m) 4.5 200 36 NT
VIII-24 Sural (s)  11 44
Deep peroneal (m) 3.3 1100 49 NT
Ulnar (s)  13 56
Ulnar (m) 2.4 6000 58 31.3
X-23 Sural (s)  13 42
Deep peroneal (m) 5.1 2000 50 49.0
Median (s)  61 55
Median (m) 3.1 13 400 55 27.0
VIII-12 Sural (s)  20 40
Deep peroneal (m) 5.1 2000 40 54.9
Median (s)  20 56
Median (m) 3.6 4700 56 30.8
Fig. 1

Neuropathology of spinal cord and peripheral nerve from patient VII-10. (A) Spinal cord section at the lumbar level demonstrating myelin pallor in fasciculus gracilis of the dorsal columns (arrows) as well as corticospinal tracts (arrowheads) (magnification ×18). Bielschowsky silver stain. (B) Section from the lumbar anterior horn demonstrating reduced numbers of motor neurons. Of the three in the centre of this section, one is pale and chromatolytic (×140). (C) Two large motor neurons in the anterior horn of the lumbar spinal cord stain intensely with the anti-phosphorylated neurofilament antibody SMI-31 (×468). (D) A large neuron in the lumbar anterior horn is surrounded by SMI-31-positive neurites (×560). (E) SMI-31-positive dystrophic neurites (×504). (FI) Toluidine blue-stained plastic sections of thoracic ventral root (F), lumbar dorsal root (G), peroneal nerve (H) and sural nerve (I) (×243). Note the reduced large fibre densities in F and G and reduced densities of all myelinated fibres in H and I.

Fig. 1

Neuropathology of spinal cord and peripheral nerve from patient VII-10. (A) Spinal cord section at the lumbar level demonstrating myelin pallor in fasciculus gracilis of the dorsal columns (arrows) as well as corticospinal tracts (arrowheads) (magnification ×18). Bielschowsky silver stain. (B) Section from the lumbar anterior horn demonstrating reduced numbers of motor neurons. Of the three in the centre of this section, one is pale and chromatolytic (×140). (C) Two large motor neurons in the anterior horn of the lumbar spinal cord stain intensely with the anti-phosphorylated neurofilament antibody SMI-31 (×468). (D) A large neuron in the lumbar anterior horn is surrounded by SMI-31-positive neurites (×560). (E) SMI-31-positive dystrophic neurites (×504). (FI) Toluidine blue-stained plastic sections of thoracic ventral root (F), lumbar dorsal root (G), peroneal nerve (H) and sural nerve (I) (×243). Note the reduced large fibre densities in F and G and reduced densities of all myelinated fibres in H and I.

Fig. 2

Ultrastructural analysis of axonal swellings from the thoracic dorsal root of case VII-10 demonstrates accumulation of numerous membrane-bound profiles at magnification ×12 280 (A) and magnification ×9520 (B). (C) Increased endoneural collagen and degenerated Schwann cell bands are seen in case VIII-18 (×7500).

Fig. 2

Ultrastructural analysis of axonal swellings from the thoracic dorsal root of case VII-10 demonstrates accumulation of numerous membrane-bound profiles at magnification ×12 280 (A) and magnification ×9520 (B). (C) Increased endoneural collagen and degenerated Schwann cell bands are seen in case VIII-18 (×7500).

Fig. 3

Neuropathology of spinal cord and peripheral nerve from patient VIII-18. (A) Spinal cord section at the thoracic level demonstrating myelin pallor in the corticospinal tracts (arrowheads) and dorsal columns (arrows). Few anterior horn cells are present in the ventral horns. Bielschowsky silver stain (magnification ×27). (B) Spinal cord section at the lumbar level demonstrating myelin pallor in fasciculus gracilis of the dorsal columns (arrowheads) as well as corticospinal tracts. Bielschowsky silver stain (×18). (C) Few anterior horn cells (arrow) are present in the ventral horn of this section of the lumbar spinal cord. Bielschowsky silver stain (×126). (D and E) Phosphorylated neurofilaments (visualized with SMI-31 antibody) accumulate in dystrophic neurites (arrows) within the ventral horn. Some of these neurites are probably surrounding degenerated motor neurons (×504). (FH) Loss of myelinated fibres in peroneal nerve (×243) (F), phrenic nerve (×243) (G) and sural nerve (×225) (H). (FH) Plastic sections stained with toluidine blue.

Fig. 3

Neuropathology of spinal cord and peripheral nerve from patient VIII-18. (A) Spinal cord section at the thoracic level demonstrating myelin pallor in the corticospinal tracts (arrowheads) and dorsal columns (arrows). Few anterior horn cells are present in the ventral horns. Bielschowsky silver stain (magnification ×27). (B) Spinal cord section at the lumbar level demonstrating myelin pallor in fasciculus gracilis of the dorsal columns (arrowheads) as well as corticospinal tracts. Bielschowsky silver stain (×18). (C) Few anterior horn cells (arrow) are present in the ventral horn of this section of the lumbar spinal cord. Bielschowsky silver stain (×126). (D and E) Phosphorylated neurofilaments (visualized with SMI-31 antibody) accumulate in dystrophic neurites (arrows) within the ventral horn. Some of these neurites are probably surrounding degenerated motor neurons (×504). (FH) Loss of myelinated fibres in peroneal nerve (×243) (F), phrenic nerve (×243) (G) and sural nerve (×225) (H). (FH) Plastic sections stained with toluidine blue.

*
Present address: A.I. duPont Hospital for Children, Wilmington, Delaware, USA
Present address: University of Washington, Seattle, Washington, USA

We thank the members of the family for their invaluable encouragement and participation, Dr Donald L. Price for valuable discussions, Dr Juan Troncoso for expert assistance with the autopsies, and Dr Justin McArthur and Mr Peter Haver for assessing the skin biopsies. This study was supported in part by the Muscular Dystrophy Association, USA, the James P. Dunn and Don and Rosalie Dietz Funds for Neuromuscular Research and the NIH (K08NS01781 to B.A.R.).

## References

Ben Hamida M, Hentati F, Ben Hamida C. Hereditary motor system diseases (chronic juvenile amyotrophic lateral sclerosis).
Brain

1990
;
113
:
347
–63.
Chance PF, Rabin BA, Ryan SG, Ding Y, Scavina M, Crain B, et al. Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34.
Am J Hum Genet

1998
;
62
:
633
–40.
Charcot J-M, Joffroy A. Deux cas d'atrophie musculaire progressive avec des lésions de la substance gris et des faisceaux antéro-latéraux de la moelle épinière.
Arch Physiol Norm Path

1869
;
2
:
54
–367, 745–60.
Chudkowicz ME, McKenna-Yasek D, Chen C, Hedley-Whyte ET, Brown RH Jr. Limited corticospinal tract involvement in amyotrophic lateral sclerosis subjects with the A4V mutation in the copper/zinc superoxide dismutase gene [see comments].
Ann Neurol

1998
;
43
:
703
–10. Comment in: Ann Neurol 1998; 43: 691–4.
Cross HE, McKusick VA. The Troyer syndrome. A recessive form of spastic paraplegia with distal muscle wasting.
Arch Neurol

1967
;
16
:
473
–85.
Dal Canto M, Gurney ME. Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu/Zn SOD1 and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS).
Brain Res

1995
;
676
:
25
–40.
Dyck PJ. Inherited neuronal degeneration and atrophy affecting peripheral motor, sensory, and autonomic neurons. In: Dyck PJ, Thomas PK, Lambert EH, editors. Peripheral neuropathy. Philadelphia: W.B. Saunders; 1975. p. 825–67.
Dyck PJ, Lambert EH. Lower motor and primary sensory neuron diseases with peroneal muscular atrophy: I. Neurologic, genetic, and electrophysiologic findings in hereditary polyneuropathies.
Arch Neurol

1968
;
18
:
603
–18.
Dyck PJ, Lambert EH. Lower motor and primary sensory neuron diseases with peroneal muscular atrophy: II. Neurologic, genetic, and electrophysiologic findings in various neuronal degenerations.
Arch Neurol

1968
;
18
:
619
–25.
Emery AEH, Holloway S. Familial motor neuron disease. In: Rowland LP, editor. Human motor neuron disease. Advances in neurology, Vol. 36. New York: Raven Press; 1982. p. 139–47.
Engel WK, Kurland LT, Klatzo I. An inherited disease similar to amyotrophic lateral sclerosis with a pattern of posterior column involvement. An intermediate form?
Brain

1959
;
82
:
203
–20.
Figlewicz D, Rouleau GA. Familial disease. In: Williams AC, editor. Motor neuron disease. London: Chapman and Hall; 1994. p. 427–50.
Fink JK, Wu CT, Jones SM, Sharp GB, Lange BM, Lesicki A, et al. Autosomal dominant familial spastic paraplegia: tight linkage to chromosome 15q.
Am J Hum Genet

1995
;
56
:
188
–92.
Garland HG, Astley CE. Hereditary spastic paraplegia with amyotrophy and pes cavus.
J Neurol Neurosurg Psychiatry

1950
;
13
:
130
–3.
Harding AE. Hereditary pure' spastic paraplegia: a clinical and genetic study of 22 families.
J Neurol Neurosurg Psychiatry

1981
;
44
:
871
–83.
Harding AE, Thomas PK. Peroneal muscular atrophy with pyramidal features.
J Neurol Neurosurg Psychiatry

1984
;
47
:
168
–72.
Hazan J, Lamy C, Melki J, Munnich A, de Recondo J, Weissenbach J. Autosomal dominant familial spastic paraplegia is genetically heterogeneous and one locus maps to chromosome 14q.
Nature Genet

1993
;
5
:
163
–7.
Hazan J, Fontaine B, Buyn RP, Lamy C, van Deutekom JC, Rime C-S, et al. Linkage of a new locus for autosomal dominant familial spastic paraplegia to chromosome 2p.
Hum Mol Genet

1994
;
3
:
1569
–73.
Hentati A, Pericak-Vance MA, Hung W-Y, Belal S, Laing N, Boustany R-M, et al. Linkage of `pure' autosomal recessive familial spastic paraplegia to chromosome 8 markers and evidence of genetic locus heterogeneity.
Hum Mol Genet

1994
;
3
:
1263
–7.
Hentati A, Bejaoui K, Pericak-Vance MA, Hentati F, Speer MC, Hung W-Y, et al. Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33-q35.
Nat Genet

1994
;
7
:
425
–8.
Hentati A, Pericak-Vance MA, Lennon F, Wasserman B, Hentati F, Juneja T, et al. Linkage of a locus for autosomal dominant familial spastic paraplegia to chromosome 2p markers.
Hum Mol Genet

1994
;
3
:
1867
–71.
Hentati A, Ouahchi K, Pericak-Vance MA, Ahmad A, Hung W-Y, Schlotter B, et al. Linkage of a common locus for recessive amyotrophic lateral sclerosis [abstract].
Am J Hum Genet

1997
;
61 Suppl 1
:
A279
.
Hirano A, Kurland LT, Sayre GP. Familial amyotrophic lateral sclerosis. A subgroup characterized by posterior and spinocerebellar tract involvement and hyaline inclusions in the anterior horn cells.
Arch Neurol

1967
;
16
:
232
–43.
Holland NR, Crawford TO, Hauer P, Cornblath DR, Griffin JW, McArthur JC. Small-fiber sensory neuropathies: clinical course and neuropathology of idiopathic cases.
Arch Neuol

1998
;
44
:
47
–59.
Keppen LD, Leppert MK, O'Connell P, Nakamura Y, Stauffer D, Lathrop M, et al. Etiological heterogeneity in X-linked spastic paraplegia.
Am J Hum Genet

1987
;
41
:
933
–43.
Kurland LT, Mulder DW. Epidemiologic investigations of amyotrophic lateral sclerosis. 2. Familial aggregations indicative of dominant inheritance.
Neurology

1955
;
5
:
182
–96, 249–68.
McCarthy BG, Hsieh ST, Stocks A, Hauer P, Macko C, Cornblath DR, et al. Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy.
Neurology

1995
;
45
:
1848
–55.
Matsumoto S, Goto S, Kusaka H, Imai T, Murakami N, Hashizume Y, et al. Ubiquitin-positive inclusion in anterior horn cells in subgroups of motor neuron diseases: a comparative study of adult-onset amyotrophic lateral sclerosis, juvenile amyotrophic lateral sclerosis and Werdnig-Hoffmann disease.
J Neurol Sci

1993
;
115
:
208
–13.
Medical Research Council. Aids to the examination of the peripheral nervous system, memorandum no. 45. London: Bailliere Tindall; 1986.
Metcalf CW, Hirano A. Amyotrophic lateral sclerosis. Clinicopathological studies of a family.
Arch Neurol

1971
;
24
:
518
–23.
Murayama S, Ookawa Y, Mori H, Nakano I, Ihara Y, Kuzuhara S, et al. Immunocytochemical and ultrastructural study of Lewy body-like hyaline inclusions in familial amyotrophic lateral sclerosis.
Acta Neuropathol (Berl)

1989
;
78
:
143
–52.
Myrianthopoulos NC, Lane MH, Silberberg DH, Vincent BL. Nerve conduction and other studies in families with Charcot–Marie–Tooth Disease.
Brain

1964
;
87
:
589
–608.
Ormerod J. An unusual form of family paralysis.
Lancet

1904
;
1
:
17
–8.
Refsum S, Skillicorn SA. Amyotrophic familial spastic paraplegia.
Neurology

1954
;
4
:
40
–7.
Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in the Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis [published erratum appears in Nature 1993; 364: 362] [see comments].
Nature

1993
;
362
:
59
–62. Comment in: Nature 1993; 362: 20–1.
Shibata N, Hirano AK, Kobayashi M, Siddique T, Deng HX, Hung WY, et al. Intense superoxide dismutase-1 immunoreactivity in intracytoplasmic hyaline inclusions of familial amyotrophic lateral sclerosis with posterior column involvement.
J Neuropathol Exp Neurol

1996
;
55
:
481
–90.
Siddique T, Nijhawan D, Hentati A. Molecular genetic basis of familial ALS. [Review].
Neurology

1996
;
47 (4 Suppl 2)
:
S27
–S35.
Silver JR. Familial spastic paraplegia with amyotrophy of the hands.
J Neurol Neurosurg Psychiatry

1966
;
29
:
135
–44.
Takahashi K, Makifuchi T, Nakano R, Sato S, Inuzuka T, Sakimura K, Mishina M, et al. Familial amyotrophic lateral sclerosis with a mutation in the Cu/Zn superoxide dismutase gene.
Acta Neuropathol (Berl)

1994
;
88
:
185
–8.
Tanaka J, Nakamura H, Tabuchi Y, Takahashi K. Familial amyotrophic lateral sclerosis: features of multisystem degeneration.
Acta Neuropathol (Berl)

1984
;
64
:
22
–9.
van Gent EM, Hoogland RA, Jennekens FGI. Distal amyotrophy of predominantly the upper limbs with pyramidal features in a large kinship.
J Neurol Neurosurg Psychiatry

1985
;
48
:
266
–9.
Webb S, Coleman D, Byrne P, Parfrey N, Burke T, Hutchinson T, et al. Autosomal dominant hereditary spastic paraparesis with cognitive loss linked to chromosome 2p.
Brain

1998
;
121
:
601
–9.
Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria.
Neuron

1995
;
14
:
1105
–16.